SENS Quote, Financials, Valuation and Earnings

Baxter International has a net margin of -562.42% compared to Senseonics Holdings's net margin of 5.19%. Senseonics Holdings's return on equity of -445.19% beat Baxter International's return on equity of 1.33%.

Senseonics Holdings has a consensus price target of --, signalling upside risk potential of 247.98%. On the other hand Baxter International has an analysts' consensus of -- which suggests that it could grow by 37.94%. Given that Senseonics Holdings has higher upside potential than Baxter International, analysts believe Senseonics Holdings is more attractive than Baxter International.

Senseonics Holdings has a beta of 0.772, which suggesting that the stock is 22.811% less volatile than S&P 500. In comparison Baxter International has a beta of 0.575, suggesting its less volatile than the S&P 500 by 42.462%.

Senseonics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 3.53% to investors and pays a quarterly dividend of $0.17 per share. Senseonics Holdings pays -- of its earnings as a dividend. Baxter International pays out 22.06% of its earnings as a dividend. Baxter International's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Senseonics Holdings quarterly revenues are $4.3M, which are smaller than Baxter International quarterly revenues of $2.7B. Senseonics Holdings's net income of -$24M is lower than Baxter International's net income of $140M. Notably, Senseonics Holdings's price-to-earnings ratio is -- while Baxter International's PE ratio is 147.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senseonics Holdings is 12.77x versus 0.87x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of -562.42% compared to Senseonics Holdings's net margin of 11.12%. Senseonics Holdings's return on equity of -445.19% beat Boston Scientific's return on equity of 8.91%.

Senseonics Holdings has a consensus price target of --, signalling upside risk potential of 247.98%. On the other hand Boston Scientific has an analysts' consensus of $99.00 which suggests that it could grow by 11.3%. Given that Senseonics Holdings has higher upside potential than Boston Scientific, analysts believe Senseonics Holdings is more attractive than Boston Scientific.

Senseonics Holdings has a beta of 0.772, which suggesting that the stock is 22.811% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

Senseonics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senseonics Holdings pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Senseonics Holdings quarterly revenues are $4.3M, which are smaller than Boston Scientific quarterly revenues of $4.2B. Senseonics Holdings's net income of -$24M is lower than Boston Scientific's net income of $468M. Notably, Senseonics Holdings's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 73.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senseonics Holdings is 12.77x versus 8.29x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -562.42% compared to Senseonics Holdings's net margin of --. Senseonics Holdings's return on equity of -445.19% beat Perspective Therapeutics's return on equity of --.

Senseonics Holdings has a consensus price target of --, signalling upside risk potential of 247.98%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than Senseonics Holdings, analysts believe Perspective Therapeutics is more attractive than Senseonics Holdings.

Senseonics Holdings has a beta of 0.772, which suggesting that the stock is 22.811% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Senseonics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senseonics Holdings pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Senseonics Holdings quarterly revenues are $4.3M, which are larger than Perspective Therapeutics quarterly revenues of --. Senseonics Holdings's net income of -$24M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Senseonics Holdings's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senseonics Holdings is 12.77x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

DexCom has a net margin of -562.42% compared to Senseonics Holdings's net margin of 13.54%. Senseonics Holdings's return on equity of -445.19% beat DexCom's return on equity of 30.96%.

Senseonics Holdings has a consensus price target of --, signalling upside risk potential of 247.98%. On the other hand DexCom has an analysts' consensus of $96.26 which suggests that it could grow by 20.27%. Given that Senseonics Holdings has higher upside potential than DexCom, analysts believe Senseonics Holdings is more attractive than DexCom.

Senseonics Holdings has a beta of 0.772, which suggesting that the stock is 22.811% less volatile than S&P 500. In comparison DexCom has a beta of 1.125, suggesting its more volatile than the S&P 500 by 12.541%.

Senseonics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DexCom offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senseonics Holdings pays -- of its earnings as a dividend. DexCom pays out -- of its earnings as a dividend.

Senseonics Holdings quarterly revenues are $4.3M, which are smaller than DexCom quarterly revenues of $994.2M. Senseonics Holdings's net income of -$24M is lower than DexCom's net income of $134.6M. Notably, Senseonics Holdings's price-to-earnings ratio is -- while DexCom's PE ratio is 47.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senseonics Holdings is 12.77x versus 8.40x for DexCom. Usually stocks with elevated PS ratios are considered overvalued.